Blog
RSS FeedPosted by Michael Wonder on 06 Jun 2018
FDA’s new efforts to advance biotechnology innovation
6 June 2018 - Scientific advances in biotechnology, such as genome editing and synthetic biology, hold enormous potential to improve human ...
Posted by Michael Wonder on 05 Jun 2018
Embracing competition to empower biosimilars
5 June 2018 - In 2017, there were 46 new novel drug innovations, including new treatments for cancers, Parkinson’s disease, ...
Posted by Michael Wonder on 30 May 2018
As part of efforts to combat opioid crisis, FDA launches innovation challenge to spur development of medical devices ‒ including digital health and diagnostics ‒ that target pain, addiction and diversion
30 May 2018 - Agency will work closely with selected applicants to accelerate product development. ...
Posted by Michael Wonder on 28 May 2018
Health insurer HCF looks to start-ups, innovation to help retain members
28 May 2018 - Australia's third largest health insurer HCF is betting on its start-up accelerator Catalyst to help it ...
Posted by Michael Wonder on 11 Apr 2018
Breakthrough-therapy designation — an FDA perspective
12 April 2018 - Recent medical advances, such as targeted therapies for specific tumour genomic defects, checkpoint inhibitors for cancers, and ...
Posted by Michael Wonder on 10 Apr 2018
Feds broaden the definition of ‘pharmacy’ in a bid to level playing field for startup
6 April 2018 - Across the US, upstart pharmacies are turning the prescription drug business on its head, offering digitally ...
Posted by Michael Wonder on 10 Apr 2018
Innovative drugs need a new regulatory approach
10 April 2018 - Innovative drugs help people enjoy longer, healthier, more productive lives. They also allow our health-care systems ...
Posted by Michael Wonder on 07 Apr 2018
New drugs: patient hope or harm?
26 March 2018 - Debate on whether new drugs are too expensive for the NHS continues to rage, and contradictory ...
Posted by Michael Wonder on 08 Mar 2018
Balancing safety and innovation for cell-based regenerative medicine
8 March 2018 - Regenerative medicine is a field that involves replacing, engineering, or regenerating human cells, tissues, or organs to ...
Posted by Michael Wonder on 13 Feb 2018
Statement from FDA Commissioner Scott Gottlieb on Administration’s request for new FDA funding to promote innovation and broaden patient access through competition
13 February 2018 - Additional resources will help advance initiatives to support novel medical technology and public health priorities such as ...
Posted by Michael Wonder on 06 Feb 2018
AusBiotech says plan to disadvantage life sciences innovation
6 February 2018 - Response to Innovation and Science Australia 2030 plan. ...
Posted by Michael Wonder on 31 Jan 2018
Industry needs clarity to invest in Australia
31 January 2018 - Medicines Australia welcomes the release of the 2030 plan by Innovation and Science Australia but seeks ...
Posted by Michael Wonder on 24 Jan 2018
How excluding some benefits from value assessment of new drugs impacts innovation
23 January 2018 - Payers often assess the benefits of new drugs relative to costs for reimbursement purposes, but they frequently ...
Posted by Michael Wonder on 09 Jan 2018
How Allergan continues to make drug prices insane
9 January 2018 - The company kept a promise to limit increases to the single digits. But it didn't stop abusing ...
Posted by Michael Wonder on 09 Jan 2018
Reflections on a landmark year for medical product innovation and public health advances and looking ahead to policy in 2018
9 January 2018 - As we look ahead to 2018, I’d like to take a moment to reflect on an ...